{"id":"W4412819491","doi":"10.1038/s41591-025-03867-5","title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Centre hospitalier de l'Université Laval","funders":"National Cancer Institute; EMD Serono; Ipsen; Servier; Astellas Pharma; Eisai; EUSA Pharma; Seagen; UroGen Pharma; F. Hoffmann-La Roche; Incyte; Daiichi Sankyo Europe; Exelixis; Merck KGaA; Gilead Sciences; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Axitinib; Sunitinib; Medicine; Hazard ratio; Renal cell carcinoma; Internal medicine; Pembrolizumab; Oncology; Clear cell renal cell carcinoma; Kidney cancer; Confidence interval; Biomarker; Cancer; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005267134,0.001011038,0.001616758,0.0002260342,0.0003403508,0.001179799,0.0006390434,0.001063732,0.00247501],"category_scores_gemma":[0.002029504,0.0003701407,0.002074373,0.0003251124,0.0005709738,0.001014718,0.0004775943,0.002437293,0.0004384471],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008533534,"about_ca_system_score_gemma":0.0009300475,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004635391,"about_ca_topic_score_gemma":0.001069852,"domain_scores_codex":[0.9984433,0.001040611,0.00006864385,0.000179044,0.0001345055,0.0001338941],"domain_scores_gemma":[0.9988537,0.0002570941,0.0003513688,0.0001297063,0.0000727417,0.0003354208],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.958914,0.004671052,0.004275322,0.0004699332,0.003091382,0.0000491213,0.00007834895,0.001839221,0.007781957,0.000156028,0.001636015,0.01703759],"study_design_scores_gemma":[0.5836016,0.3422768,0.05486892,0.0001046121,0.004467763,0.0002793938,0.0001250508,0.005398327,0.004171078,0.0007359263,0.003894589,0.00007596384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941351,0.002754228,0.0003334201,0.000276136,0.000104472,0.0003715895,0.0007731701,0.00004282397,0.001209045],"genre_scores_gemma":[0.9952735,0.000744434,0.0005157617,0.0004106719,0.0001365474,0.0005493021,0.001468226,0.00001490673,0.0008866317],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005267134,"threshold_uncertainty_score":0.02785558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05595577496506752,"score_gpt":0.3804246357242225,"score_spread":0.3244688607591549,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}